key: cord-268155-b8lqo52f
authors: Farrugia, Albert
title: Plasma from donors convalescent from SARS-CoV-2 infection – A matter of priorities
date: 2020-06-12
journal: Transfus Clin Biol
DOI: 10.1016/j.tracli.2020.05.002
sha: 
doc_id: 268155
cord_uid: b8lqo52f

nan

, (8) it is therefore preferable that the collection of CP for the treatment of patients continues unhampered until the epidemic wanes and the urgent need of transfusable CP decreases. In the interim, donor panels for hyperimmune Ig production may be constructed and an optimal path for the provision of this medicine may be developed, hopefully with harmonisation between the major regulatory agencies. This parallel path will cover the demand for treatment as well as generating hyperimmune Ig for the protection of select groups. For the general population, provision of enough Ig is unlikely and will not provide long-term protection, and hence a vaccine is eagerly awaited.

Finally, in the rapidly developing field of therapeutics to Covid-19 infection, continued vigilance is required to ensure ethical principles are maintained. Convalescent plasma harvested from voluntary donors in state blood services is at risk of being deflected from therapeutic use through preferential patient allocation to clinical trials for other Covid-19 therapies funded by large pharmaceutical companies. The evidence base of some of these therapies is nebulous, and patient allocation to such trials, which needs to include control arms, may result in disadvantage to patients (9) . Given the continued body of evidence and public effort in the collection and use of convalescent plasma, it is to be hoped that this treatment will be considered as a first line modality and will not be obstructed by commercial considerations. In particular, a transparent, publicly-driven process is required, given that mechanisms have been developed to facilitate commercial companies' access to patients and patient organisations, a development which needs to be viewed with concern (10).

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19

Hyperimmune Therapy

Donor centers for convalescent plasma

The Separation of the Antibodies, Isoagglutinins, Prothrombin, Plasminogen and β1-Lipoprotein into Subfractions of Human Plasma

Purification of human immunoglobulin G: a new approach to plasma fractionation

Optimised affinity purification of polyclonal antibodies from hyper immunised ovine serum using a synthetic Protein A adsorbent, MAbsorbent® A2P

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv

Physicians And The Patient Recruitment Problem